Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized tRial Employing topiCal roflumilasT Foam to Treat Scalp Psoriasis (ARRECTOR)

Next Previous
X
Search
Trial Profile

A Randomized tRial Employing topiCal roflumilasT Foam to Treat Scalp Psoriasis (ARRECTOR)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms ARRECTOR
  • Sponsors Arcutis Biotherapeutics

    • Most Recent Events

    • 23 Jul 2024 According to an Arcutis Biotherapeutics media release, the company announced submission of a supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) foam 0.3%, a once-daily,for the treatment of adults and adolescents ages 12 and over with scalp and body psoriasis.
    • 20 May 2024 According to an Arcutis Biotherapeutics media release, the Company anticipates submitting an sNDA for scalp and body psoriasis to the FDA in the third quarter of 2024, Based on the positive topline results from this trial.
    • 12 Mar 2024 Results of Patient-reported outcomes , presented at the American Academy of Dermatology annual Meeting 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top